ATE500263T1 - Neue 2',3'-methylidenacetyladenosine prodrugs zur verwendung als adenosinrezeptoragonisten - Google Patents

Neue 2',3'-methylidenacetyladenosine prodrugs zur verwendung als adenosinrezeptoragonisten

Info

Publication number
ATE500263T1
ATE500263T1 AT07765638T AT07765638T ATE500263T1 AT E500263 T1 ATE500263 T1 AT E500263T1 AT 07765638 T AT07765638 T AT 07765638T AT 07765638 T AT07765638 T AT 07765638T AT E500263 T1 ATE500263 T1 AT E500263T1
Authority
AT
Austria
Prior art keywords
drugs
compounds
receptor agonists
adenosine receptor
pro
Prior art date
Application number
AT07765638T
Other languages
German (de)
English (en)
Inventor
Edward Daniel Savory
Original Assignee
Cbt Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cbt Dev Ltd filed Critical Cbt Dev Ltd
Application granted granted Critical
Publication of ATE500263T1 publication Critical patent/ATE500263T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT07765638T 2006-06-27 2007-06-26 Neue 2',3'-methylidenacetyladenosine prodrugs zur verwendung als adenosinrezeptoragonisten ATE500263T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0601396 2006-06-27
US83730806P 2006-08-11 2006-08-11
PCT/EP2007/056375 WO2008000743A2 (en) 2006-06-27 2007-06-26 Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists

Publications (1)

Publication Number Publication Date
ATE500263T1 true ATE500263T1 (de) 2011-03-15

Family

ID=38545430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07765638T ATE500263T1 (de) 2006-06-27 2007-06-26 Neue 2',3'-methylidenacetyladenosine prodrugs zur verwendung als adenosinrezeptoragonisten

Country Status (12)

Country Link
US (1) US7906518B2 (enExample)
EP (1) EP2066685B1 (enExample)
JP (1) JP2009541436A (enExample)
CN (1) CN101479290A (enExample)
AT (1) ATE500263T1 (enExample)
AU (1) AU2007263726A1 (enExample)
BR (1) BRPI0713901A2 (enExample)
CA (1) CA2657973A1 (enExample)
DE (1) DE602007012904D1 (enExample)
ES (1) ES2361886T3 (enExample)
RU (1) RU2009102512A (enExample)
WO (1) WO2008000743A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102014959B (zh) * 2008-03-10 2016-01-20 康奈尔大学 血脑屏障通透性的调节
WO2010080540A1 (en) * 2008-12-18 2010-07-15 Inspire Pharmaceuticals, Inc. Method for treating inflammatory conditions
RU2478392C2 (ru) * 2011-05-20 2013-04-10 Евгений Петрович Измайлов Способ консервативного и физиотерапевтического лечения серозно-геморрагического плеврита
RU2478391C2 (ru) * 2011-05-20 2013-04-10 Евгений Петрович Измайлов Способ физиотерапевтического и консервативного лечения плеврита
US9822141B2 (en) 2012-08-01 2017-11-21 Lewis And Clark Pharmaceuticals, Inc. N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists
EP2879683B1 (en) * 2012-08-01 2020-01-22 Lewis and Clark Pharmaceuticals, Inc. N-alkyl-alkynyladenosine-5-uronamide compounds as agonists of a2a receptor
US11541071B1 (en) * 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US5691188A (en) * 1994-02-14 1997-11-25 American Cyanamid Company Transformed yeast cells expressing heterologous G-protein coupled receptor
US6498149B1 (en) 1997-06-03 2002-12-24 Tsuneatsu Mori Natural antitumor or antiviral substances and use of the same
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6958324B2 (en) * 1998-12-02 2005-10-25 Inotek Pharmaceuticals Corporation Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
AU2001238342A1 (en) * 2000-02-17 2001-08-27 Cv Therapeutics, Inc. Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation
US6995148B2 (en) * 2001-04-05 2006-02-07 University Of Pittsburgh Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
US6713638B2 (en) * 2001-05-18 2004-03-30 Joel M. Linden 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305150D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Use of therapeutic compounds
GB0305149D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
JP2007506804A (ja) * 2003-06-09 2007-03-22 エンダセア， インコーポレイテッド Ａ１アデノシンレセプターアンタゴニスト
DE602004017005D1 (de) * 2003-07-22 2008-11-20 Cv Therapeutics Inc A1 adenosin-rezeptor-antagonisten
BRPI0412577A (pt) * 2003-07-31 2006-09-19 Sanofi Aventis derivados de aminoquinolina e seu uso como ligantes de adenosina a3
US7504497B2 (en) * 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
EP1685135B1 (en) * 2003-10-21 2010-05-26 Inspire Pharmaceuticals, Inc. TETRAHYDRO-FURO[3,4-d]DIOXOLE COMPOUNDS AND COMPOSITIONS AND METHOD FOR INHIBITING PLATELET AGGREGATION
JP2007509180A (ja) * 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ，インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
MXPA06010075A (es) * 2004-03-05 2007-04-10 Cambridge Biotechnology Ltd Compuestos terapeuticos.
AU2005231440B9 (en) * 2004-04-02 2012-02-23 Dogwood Pharmaceuticals, Inc. Selective antagonists of A2A adenosine receptors
JP2007536241A (ja) * 2004-05-03 2007-12-13 ユニバーシティ オブ バージニア パテント ファウンデーション 糖尿病性腎症の処置のためのａ２ａアデノシンレセプターアゴニスト
JP2008508319A (ja) * 2004-07-29 2008-03-21 メタバシス・セラピューティクス・インコーポレイテッド 新規ヌクレオシド誘導体
WO2006031505A1 (en) * 2004-09-09 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Purine derivatives as a3 and a1 adenosine receptor agonists
US8461128B2 (en) * 2005-04-15 2013-06-11 Sloan-Kettering Institute For Cancer Research Anti-microbial agents and uses thereof
US7514417B2 (en) * 2005-05-19 2009-04-07 Cv Therapeutics, Inc. A1 adenosine receptor agonists
GB0514809D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
KR101383228B1 (ko) * 2006-01-26 2014-04-09 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 레프리젠티드 바이 더 세크러터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비스즈 Ａ3 아데노신 수용체 알로스테릭 조절제
WO2007092936A2 (en) * 2006-02-08 2007-08-16 University Of Virginia Patent Foundation Method to treat gastric lesions
EP1989210A2 (en) * 2006-03-02 2008-11-12 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
JP5250848B2 (ja) * 2006-03-17 2013-07-31 ギリアード サイエンシーズ， インコーポレイテッド Ａ２ｂアデノシン受容体拮抗物質を用いる肝疾患の予防および処置の方法
US20070299089A1 (en) * 2006-06-22 2007-12-27 Cv Therapeutics, Inc. Use of A2A Adenosine Receptor Agonists in the Treatment of Ischemia
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
US7723343B2 (en) * 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
WO2008124150A1 (en) * 2007-04-09 2008-10-16 University Of Virginia Patent Foundation Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist
US20080262001A1 (en) * 2007-04-23 2008-10-23 Adenosine Therapeutics, Llc Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection
US8153781B2 (en) * 2007-06-29 2012-04-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Dendrimer conjugates of agonists and antagonists of the GPCR superfamily
EP2200615A1 (en) * 2007-10-16 2010-06-30 Gilead Palo Alto, Inc. A3 adenosine receptor antagonists
WO2009061516A1 (en) * 2007-11-08 2009-05-14 New York University School Of Medicine Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening
JP2011509305A (ja) * 2008-01-09 2011-03-24 ピージーエックスヘルス、リミテッド、ライアビリティー、カンパニー Ａ２ａｒアゴニストによる神経障害性疼痛の髄腔内治療
JP2011511802A (ja) * 2008-02-07 2011-04-14 ギリアード・パロ・アルト・インコーポレイテッド Ａｂｃａ−１を上昇させる化合物およびかかる化合物の使用方法

Also Published As

Publication number Publication date
CA2657973A1 (en) 2008-01-03
WO2008000743A2 (en) 2008-01-03
RU2009102512A (ru) 2010-08-10
EP2066685B1 (en) 2011-03-02
WO2008000743A3 (en) 2008-02-21
AU2007263726A1 (en) 2008-01-03
US7906518B2 (en) 2011-03-15
EP2066685A2 (en) 2009-06-10
US20080027081A1 (en) 2008-01-31
JP2009541436A (ja) 2009-11-26
ES2361886T3 (es) 2011-06-24
DE602007012904D1 (de) 2011-04-14
CN101479290A (zh) 2009-07-08
BRPI0713901A2 (pt) 2013-01-08

Similar Documents

Publication Publication Date Title
ATE500263T1 (de) Neue 2',3'-methylidenacetyladenosine prodrugs zur verwendung als adenosinrezeptoragonisten
PE20160195A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
SMT201300095B (it) Uso dell'estere etilico dell'acido eicosapentaenoico per trattare l'ipertrigliceridemia
EA201000914A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
BR112012009376A2 (pt) composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
EA201200002A1 (ru) Производные индоламида и родственные соединения для использования при лечении нейродегенеративных заболеваний
MXPA05011208A (es) Uso de ivermectina para el tratamiento de desordenes dermatologicos.
CL2007003440A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida
ECSP10010289A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
BR0316364A (pt) Combinação de terapia do câncer com um composto anticâncer ativado com gst e uma outra terapia anticâncer
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
PL2043637T3 (pl) Sposoby i leki do podawania ibuprofenu
WO2012142615A3 (en) Auranofin and auranofin analogs useful to treat proliferative disease and disorders
SE0400184D0 (sv) New therapeutical use
EA200870469A1 (ru) Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение
BRPI0509927A (pt) composição farmacêutica, uso de uma composição de matéria, e, uso de uma combinação terapeuticamente eficaz de um oligonucleotìdeo anti-sentido de survivina e cloridrato de gemcitabina
BRPI0415215B8 (pt) uso de polifenol na preparação de medicamento
BRPI0409796A (pt) uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina
NO20044498L (no) Kombinasjonsterapi for behandling av cancer
ATE485037T1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
MX2010006724A (es) Regimenes terapeuticos para el tratamiento de desordenes inmunoinflamatorios.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties